Morgan Stanley Landos Biopharma, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.22 - $0.51 $1,734 - $4,021	-7,885 Reduced 91.12%	768 $0
Q3 2022 Nov 14, 2022	SELL	$0.67 - $1.26 $667 - $1,254	-996 Reduced 10.32%	8,653 $5,000
Q2 2022 Oct 27, 2022	BUY	$0.6 - $1.5 $1,433 - $3,583	2,389 Added 32.91%	9,649 $8,000
Q2 2022 Aug 15, 2022	BUY	$0.6 - $1.5 $1,433 - $3,583	2,389 Added 32.91%	9,649 $8,000
Q1 2022 Oct 27, 2022	SELL	$1.44 - $5.22 $3,440 - $12,470	-2,389 Reduced 24.76%	7,260 $11,000
Q1 2022 May 13, 2022	SELL	$1.44 - $5.22 $210,983 - $764,813	-146,516 Reduced 95.28%	7,260 $11,000
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $714,555 - $2.28 Million	152,033 Added 8722.49%	153,776 $738,000
Q3 2021 Nov 15, 2021	BUY	$9.77 - $15.77 $17,029 - $27,487	1,743 New	1,743 $26,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.